Literature DB >> 1518863

Tetrapeptide inhibitors of protein farnesyltransferase: amino-terminal substitution in phenylalanine-containing tetrapeptides restores farnesylation.

M S Brown1, J L Goldstein, K J Paris, J P Burnier, J C Marsters.   

Abstract

Protein farnesyltransferase from rat brain transfers farnesyl residues to cysteine residues in tetrapeptides that conform to the sequence CA1A2X, where C is cysteine, A1 and A2 are aliphatic amino acids, and X is methionine or serine. When the A2 residue is aromatic [e.g., phenylalanine as in Cys-Val-Phe-Met (CVFM)], the tetrapeptide continues to bind to the enzyme, but it can no longer accept a farnesyl group, and it becomes a pure inhibitor. The current studies show that this resistance to farnesylation also requires a positive charge on the cysteine amino group. Derivatization of this group with acetyl, octanoyl, or cholic acid residues or extension of the peptide with an additional amino acid restores the ability of phenylalanine-containing peptides to accept a farnesyl residue. The same result was obtained when the amino group of cysteine was deleted (mercaptopropionyl-VFM). These data suggest that the positive change on the cysteine amino group acts in concert with an aromatic residue in the A2 position to render peptides resistant to farnesylation by the rat brain enzyme.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1518863      PMCID: PMC49908          DOI: 10.1073/pnas.89.17.8313

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  13 in total

1.  Nonidentical subunits of p21H-ras farnesyltransferase. Peptide binding and farnesyl pyrophosphate carrier functions.

Authors:  Y Reiss; M C Seabra; S A Armstrong; C A Slaughter; J L Goldstein; M S Brown
Journal:  J Biol Chem       Date:  1991-06-05       Impact factor: 5.157

2.  Cloning and expression of a cDNA encoding the alpha subunit of rat p21ras protein farnesyltransferase.

Authors:  W J Chen; D A Andres; J L Goldstein; M S Brown
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-15       Impact factor: 11.205

3.  Inhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptides.

Authors:  Y Reiss; J L Goldstein; M C Seabra; P J Casey; M S Brown
Journal:  Cell       Date:  1990-07-13       Impact factor: 41.582

4.  Divalent cation and prenyl pyrophosphate specificities of the protein farnesyltransferase from rat brain, a zinc metalloenzyme.

Authors:  Y Reiss; M S Brown; J L Goldstein
Journal:  J Biol Chem       Date:  1992-03-25       Impact factor: 5.157

5.  Protein farnesyltransferase and geranylgeranyltransferase share a common alpha subunit.

Authors:  M C Seabra; Y Reiss; P J Casey; M S Brown; J L Goldstein
Journal:  Cell       Date:  1991-05-03       Impact factor: 41.582

6.  cDNA cloning and expression of the peptide-binding beta subunit of rat p21ras farnesyltransferase, the counterpart of yeast DPR1/RAM1.

Authors:  W J Chen; D A Andres; J L Goldstein; D W Russell; M S Brown
Journal:  Cell       Date:  1991-07-26       Impact factor: 41.582

7.  Nonfarnesylated tetrapeptide inhibitors of protein farnesyltransferase.

Authors:  J L Goldstein; M S Brown; S J Stradley; Y Reiss; L M Gierasch
Journal:  J Biol Chem       Date:  1991-08-25       Impact factor: 5.157

8.  Sequence dependence of protein isoprenylation.

Authors:  S L Moores; M D Schaber; S D Mosser; E Rands; M B O'Hara; V M Garsky; M S Marshall; D L Pompliano; J B Gibbs
Journal:  J Biol Chem       Date:  1991-08-05       Impact factor: 5.157

9.  Enzymatic modification of proteins with a geranylgeranyl isoprenoid.

Authors:  P J Casey; J A Thissen; J F Moomaw
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-01       Impact factor: 11.205

10.  Sequence requirement for peptide recognition by rat brain p21ras protein farnesyltransferase.

Authors:  Y Reiss; S J Stradley; L M Gierasch; M S Brown; J L Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-01       Impact factor: 11.205

View more
  6 in total

1.  Membrane-associated farnesylated UCH-L1 promotes alpha-synuclein neurotoxicity and is a therapeutic target for Parkinson's disease.

Authors:  Zhihua Liu; Robin K Meray; Tom N Grammatopoulos; Ross A Fredenburg; Mark R Cookson; Yichin Liu; Todd Logan; Peter T Lansbury
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-04       Impact factor: 11.205

Review 2.  Targeting Metalloenzymes for Therapeutic Intervention.

Authors:  Allie Y Chen; Rebecca N Adamek; Benjamin L Dick; Cy V Credille; Christine N Morrison; Seth M Cohen
Journal:  Chem Rev       Date:  2018-09-07       Impact factor: 60.622

3.  The crystal structure of human protein farnesyltransferase reveals the basis for inhibition by CaaX tetrapeptides and their mimetics.

Authors:  S B Long; P J Hancock; A M Kral; H W Hellinga; L S Beese
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-30       Impact factor: 11.205

Review 4.  Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease.

Authors:  Behzad Yeganeh; Emilia Wiechec; Sudharsana R Ande; Pawan Sharma; Adel Rezaei Moghadam; Martin Post; Darren H Freed; Mohammad Hashemi; Shahla Shojaei; Amir A Zeki; Saeid Ghavami
Journal:  Pharmacol Ther       Date:  2014-02-26       Impact factor: 12.310

5.  A mechanism for posttranslational modifications of proteins by yeast protein farnesyltransferase.

Authors:  J M Dolence; C D Poulter
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-23       Impact factor: 11.205

6.  Manumycin and gliotoxin derivative KT7595 block Ras farnesylation and cell growth but do not disturb lamin farnesylation and localization in human tumour cells.

Authors:  T Nagase; S Kawata; S Tamura; Y Matsuda; Y Inui; E Yamasaki; H Ishiguro; T Ito; J Miyagawa; H Mitsui; K Yamamoto; M Kinoshita; Y Matsuzawa
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.